{
  "abstract": "Mummery et al 1 outline the recommendations for the appropriate use (AURs) of the amyloid-targeting monoclonal antibody lecanemab in clinical practice in the United Kingdom. These recommendations are published more than a year after the UK Medicines and Healthcare products Regulatory Agency’s (MHRA) regulatory approval in August 2024.",
  "authors": [
    {
      "affiliations": [
        "National Center for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy"
      ],
      "name": "Antonio Ancidoni"
    }
  ],
  "title": "Appropriate use recommendations in search of reimbursement: lecanemab and the UK dilemma",
  "uid": "9f47b31a-1fa8-532b-a237-212f915a2dfb"
}